In the pre-clinical, clinical, and production stages of drug development, a series of bioanalytical experiments are needed to characterize drug efficacy, affinity, and quality. For example: toxicity / pharmacokinetics (TK / PK), pharmacodynamics / biomarkers (PD / biomarker), anti-drug antibodies (ADA), impurity analysis (protein A, HCP).

Fast, automated, micro-detection, and high sensitivity are critical to speed up the time to enter the market, reduce costs, get reliable data, and develop successful drugs. The use of non-invasive test tubes, such as liquid biopsy, will find and discover valuable biomarkers which will become an important hot spot in the current research.

Bioanalytical testing has accumulated a large number of proven analytical and biomarker methods. Due to the increasing innovation in these biomarkers, some innovations are actively developing and validating assay technologies. Cell-based bioanalysis includes: immunogenetic testing, metabolomics, ADME 14C, method transfer, development, optimization and validation, PD bioanalysis (biomarkers), PK bioanalysis (small molecules and biopharmaceuticals)

Innovative technologies use a wide range of rapid analysis including mass spectrometry (LC-MS/MS), immunochemistry, UPLC ultra-high performance liquid chromatography, preparation of samples using automated techniques or turbulent techniques, etc... Applying products represented by Code Biotech, it is superior in the application of cutting-edge technology in bioanalysis.